Mail-order testosterone is going mainstream.
What’s happening: Hims & Hers entered hormonal health, striking an exclusive partnership with Marius Pharmaceuticals for an oral TRT pill while preparing menopause HRT offerings.
Capital T. With its GLP-1 push slowed by a feud with Novo Nordisk, the telehealth company is targeting 20M American men with low T.
Starting with compounded off-label meds paired with ED pills, the platform will add FDA-approved oral and injectable testosterone therapies next year. A schedule III drug, TRT will run through recently acquired Trybe Labs for diagnosis and clinical consults.
Real issues. As rival Ro aligns with Big Pharma and enlists Serena Williams to normalize GLP-1s, Hims and others see an opening in hormones.
Shedding stigma and regulation, telehealth companies are prescribing men’s and women’s HRT as the market approaches $35B. Noom and WeightWatchers launched menopause-specific programs, while Joi + Blokes and Hone Health court healthspan optimizers of both sexes.
Punchline: Hims & Hers isn’t afraid to skirt regulations to become the “Netflix of healthcare.” Now, it’s betting hormonal health will be its next blockbuster.
